[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-connectivity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-connectivity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,83,117,139,173,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100648036","connectome-guided-onco-functional-resection-with-tractography-extended-neuronavigation-in-brain-tumor-surgery-100648036",false,"NCT07717827","Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery","Connectome-guided Onco-functional Resection With Tractography-Extended Neuronavigation in Brain Tumor Surgery Involving Eloquent Regions: a Prospective Single-centre Cohort Study Integrating Advanced Diffusion MRI Into Clinical Neuronavigation for Gliomas and Metastases","CORTEx","Inclusion Criteria:\n\n* Indication for supratentorial brain tumor surgery (glioma or metastasis)\n* Lesion located within or adjacent to eloquent cortical or subcortical regions (motor, language, visual, or higher-order associative networks, as defined by clinical and neuroimaging criteria)\n* Availability of standardized preoperative and early postoperative brain MRI (including high-direction diffusion tensor imaging, ≥64 directions)\n* Consistent postoperative clinical follow-up planned at the treating centre\n* Provision of informed consent for use of anonymized clinical and imaging data\n\nExclusion Criteria:\n\n* Inability to undergo pre- or postoperative MRI\n* Significant comorbidities precluding surgery\n* Incomplete imaging or clinical data\n* Purely infratentorial lesions or non-tumoral pathologies","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Brain tumor surgery in so-called \"eloquent\" brain areas aims to remove as much tumor as possible while preserving neurological functions. Standard surgical planning typically focuses on discrete, anatomically defined cortical regions. However, modern neuroscience demonstrates that most brain functions arise from distributed networks of interconnected areas rather than isolated spots - a concept that standard navigation tools do not fully capture.\n\nThe CORTEX study evaluates a surgical workflow - termed \"connectome-guided network-based navigation\" - in which advanced diffusion MRI processing is used to reconstruct patient-specific maps of white matter pathways and large-scale brain networks. These maps are imported into a clinical neuronavigation system to guide preoperative planning and intraoperative decision-making for patients with gliomas or brain metastases in eloquent regions.\n\nThe primary aims are to determine how often network-based information leads to meaningful changes in surgical strategy compared with conventional anatomy-based planning, and to assess early neurological outcomes. Secondary objectives include characterizing the extent of tumor removal, the proximity of the resection to critical white matter tracts, and the feasibility of implementing this pipeline in a high-volume clinical setting.",[25,26,27,28],"Brain (Nervous System) Cancers","Glioma","Brain Metastasases","Brain Connectivity",[30,31,32,33,34,35,36,37,38,39,40,41,42,15],"diffusion MRI","tractography","neuronavigation","connectome","eloquent cortex","brain tumor surgery","white matter","glioma","brain metastasis","extent of resection","onco-functional balance","network neuroscience","neural networks","RECRUITING","2026-07-16",{"date":46,"type":47},"2026-07-21","ACTUAL",{"date":49,"type":47},"2022-01-01",{"date":51,"type":21},"2027-12",{"name":53,"class":54},"ARNAS Civico Di Cristina Benfratelli Hospital","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":55},"100599977","glucagon-like-peptide-1-glp-1-receptor-agonist-therapy-and-exercise-training-in-people-with-obesity-100599977","NCT07091500","Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity","Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity","Inclusion Criteria:\n\n* i) obesity (Body Mass Index ≥ 30 kg\u002Fm2)\n* ii) decreased physical function (Modified Physical Performance Test score 17 to 31)\n* iii) approval of their primary physician to participate in this study.\n\nExclusion Criteria:\n\n* i) unstable weight (\\>4% change during the last 2 months before entering the study)\n* ii) ≥150 min per week of structured exercise (e.g., jogging, activities that cause heavy breathing and sweating)\n* iii) diabetes\n* iv) significant cardiopulmonary disease (heart failure, angina, uncontrolled hypertension, chronic obstructive pulmonary disease) or other organ dysfunction (e.g., renal insufficiency \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* v) therapy with a GLP-1 or other weight loss medications\n* vi) clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal motility\n* vii) history of chronic or acute pancreatitis\n* viii) thyroid-stimulating hormone (TSH) \\>1.5X the upper limit of normal (patients receiving treatment for hypothyroidism may be included provided their thyroid hormone replacement dose has been stable for at least 3 months)\n* ix) history of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 months that would interfere with study participation\n* x) acute or chronic hepatitis, or other liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)\n* xi) family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* xii) history of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n* xiii) tobacco use, excessive alcohol intake (≥3 drinks\u002Fday for men and ≥2 drinks\u002Fday for women) or active substance abuse with illegal drugs by self-report, or regular marijuana use within 3 months of enrollment and unwilling to abstain from marijuana during the trial\n* xiv) Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study\n* xv) have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity\n* xvi) anemia (Hgb \\\u003C10 g\u002FdL)\n* xvii) Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)\n* xii) history of seizure disorder\n* xix) Female who is pregnant, breast-feeding or intends to become pregnant\n* xx) allergy or hypersensitivity to GLP-1 RA medications\n* xxi) unable to grant voluntary informed consent\n* xxii) unable or unwilling to follow the study protocol or who, for any reason, the research team considers the participant is not an appropriate candidate for the study","50 Years","75 Years",{"count":66,"type":21},40,"INTERVENTIONAL",[69],"NA","The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied.\n\nIn this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle, physical and metabolic function, muscle strength and appetite control and reward signaling in the brain in response to 1-year of GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle and appetite-related outcomes assessed 1-year after stopping treatment.",[72,73,28],"Obesity","Skeletal Muscle","2026-07-08",{"date":76,"type":47},"2026-07-10",{"date":78,"type":47},"2025-08-11",{"date":80,"type":21},"2029-08-01",{"name":82,"class":54},"Washington University School of Medicine",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":95,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100586047","whole-brain-dynamics-in-the-natural-menstrual-cycle-vs-an-ovarian-stimulated-cycle-impact-of-hormonal-fluctuations-on-healthy-women-undergoing-ovarian-stimulation-100586047","NCT06910293","Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on Healthy Women Undergoing Ovarian Stimulation","Inclusion Criteria:\n\n* Age group: 25 - 35 years old\n* BMI: 20 - 30\n* Anti-Mullerian Hormone (AMH): 1.3 - 5.9 ng\u002Fml\n* Regular Menstrual Cycle: 26-35 days\n* In case of previous use of hormonal contraception: wash-out period of 3 month\n* Meet standard safety and eligibility criteria for MRI scanning, including the absence of contraindications such as metallic implants, claustrophobia, or other medical conditions that preclude MRI\n\nExclusion Criteria:\n\n* History of ovarian surgery\n* Pathology of the ovaries\n* Mental health disorders\n* Use of medication influencing brain function\n* Ongoing use of hormonal contraception (this would include OCP, but also patches and Mirena containing IUD)",true,"FEMALE","25 Years","35 Years",{"count":94,"type":21},15,"8 Weeks","The investigators aim is to investigate the brain's dynamic complexity across three phases of an ovarian stimulation cycle (basal, pre-OPU, mid-luteal), to observe the impact of externally administered hormones, and compare it with the corresponding phases of a natural menstrual cycle (early follicular, pre-ovulatory, mid-luteal) in the same woman. Brain activity patterns will be examined using resting-state fMRI in a sample of young, healthy, naturally cycling women.",[98,99,100,28],"Neural Activity","Brain Function","Neurodynamics",[102,103,104,105,106],"Menstrual Cycle","Ovarian Stimulated Cycle","Endocrine Profile","neural activity","neurodynamics","2026-06-22",{"date":109,"type":47},"2026-06-23",{"date":111,"type":47},"2025-04-07",{"date":113,"type":21},"2026-12-31",{"name":115,"class":54},"ART Fertility Clinics LLC",2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":67,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":55},"100464018","resting-state-changes-following-theta-burst-stimulation-100464018","NCT05322239","Resting State Changes Following Theta Burst Stimulation","Novel Electric-field Modelling Approach to Quantify Changes in Resting State Functional Connectivity Following Theta Burst Stimulation","Inclusion Criteria\n\n* Able to give their consent\n* Right-handed\n\nExclusion Criteria\n\n* Non-english speaking\n* Any significant medical problems\n* Current or past Axis I psychiatric disorder(s),\n* Active or history of active suicidal ideation\n* Alcohol\u002Fdrug problems in the past year or lifetime alcohol or drug dependence\n* Medications that act on the central nervous system\n* History of seizure\n* History of epilepsy or other neurological problems\n* Increased risk of seizure for any reason\n* Pregnancy\n* Any medical condition that increases risk for fMRI or TMS\n* Any metal in their body which would make having an MRI scan unsafe\n* Any sort of medical implants\n* Claustrophobia","60 Years",{"count":126,"type":21},200,[69],"Transcranial magnetic stimulation (TMS) is increasingly being applied to effectively treat mental illness, however efforts to quantify the effects of TMS on the network architecture of the brain have largely been limited in scope and tied to specific neurologic and psychiatric disorders. The objective of the current work is to build and validate a whole-brain, domain-general model of brain connectivity changes following TMS, based on physical models of the current distribution at the cortex. PUBLIC HEALTH RELEVANCE: This work is relevant to public health because it will provide direct evidence that brain connectivity changes following neuromodulatory TMS vary as a function of the current density at the cortex, which can be used to predict psychiatric symptom change following neuromodulatory TMS.",[28],"2026-01-06",{"date":132,"type":47},"2026-01-07",{"date":134,"type":47},"2022-11-17",{"date":136,"type":21},"2027-08-01",{"name":138,"class":54},"Nicholas Balderston, PhD",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":89,"sex":17,"minAge":124,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":67,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":55},"100560170","neurophysiological-changes-after-perturbation-based-training-in-older-adults-100560170","NCT06573658","Neurophysiological Changes After Perturbation-based Training in Older Adults","Short-term Neurophysiological Changes After a Perturbation-based Training in Community-dwelling Older Adults: A Pilot Study","Inclusion Criteria:\n\n* Aged ≥ 60 years old\n* Community-dwelling\n* Right-handed\n* Able to communicate effectively in Cantonese or Mandarin\n* Able to walk independently on level ground for ≥ 30 minutes\n* Abbreviated Mental Test (Hong Kong version) score ≥ 6\n\nExclusion Criteria:\n\n* Metal implants (e.g. pacemaker, artificial cochlea)\n* Uncorrected vision or hearing impairment\n* Osteoporosis\n* Hip or knee replacement within the last year\n* Musculoskeletal, cardiovascular, mental, or neurological disorders (such as Parkinson's disease) which can affect MRI examination, balance control, or exercise participation.",{"count":147,"type":21},88,[69],"This is an assessor-blinded neurophysiological study. Participants will be randomly assigned to a perturbation-based training (PBT) or a walking (control) group. Changes in postural stability and neurophysiology in the brain following PBT compared to walking exercise without perturbation will be investigated.",[151,152,153,28,154],"Falling","Community Dwelling Older Adults","Postural Stability","Brain Structure",[156,157,158,159,160,161,162,163],"Perturbation","Magnetic Resonance Image","MRI","step training","responsive postural control","balance","external disturbance","fall","2025-09-19",{"date":166,"type":47},"2025-09-24",{"date":168,"type":47},"2024-04-18",{"date":170,"type":21},"2026-10-14",{"name":172,"class":54},"The Hong Kong Polytechnic University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":183,"conditions":184,"keywords":192,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100533123","predicting-treatment-outcomes-in-refractory-constipation-through-brain-connectivity-evaluation-100533123","NCT06221722","Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation","Evaluation of Brain Connectivity Function in Predicting Therapeutic Effects in Patients With Refractory Constipation: a Multicenter, Prospective, Cohort Study","Inclusion Criteria:\n\n* 18≤ age ≤ 45 years old\n* Right-handed\n* Patients diagnosed as functional constipation according to the Rome IV criteria\n* Informed consent of patients\n\nExclusion Criteria:\n\n* Complicated with gastrointestinal organic disease or significant functional abnormalities (tuberculosis, polyps, Crohn's disease, tumors, congenital megacolon, pelvic floor muscle relaxation, abnormal colonic transit test, etc.)\n* Long-term intense exercise (continuous exercise for more than 8 hours per week, such as marathon runners or triathletes)\n* No history of chronic pain, no recent major trauma\n* Drug abuse or tobacco dependence (half a pack or more per day)\n* Combined hypothyroidism and Parkinson's disease\n* Patients with confirmed mental illness or neurological disorders who take psychotropic drugs, analgesics or hormones\n* History of abdominal surgery (appendectomy, hysterectomy, or cholecystectomy)\n* Contraindications to functional magnetic resonance imaging (claustrophobia, metal implants)\n* Pregnant or lactating women with constipation after delivery\n* Patients with other benign and malignant tumors and autoimmune diseases\n* Infectious diseases such as hepatitis B, hepatitis C, AIDS, etc.\n* Heart disease, organ failure and other chronic diseases that require long-term medication or affect the quality of life","45 Years",{"count":182,"type":21},150,"The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are:\n\n* Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients\n* Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation.\n\nParticipants will receive:\n\n* Standard physiological and psychological assessments of constipation\n* BOLD-fMRI tests\n* Standard protocol and fluoxetine treatment\n\nIf there is a comparison group: Researchers will compare:\n\nRefractory group\u002FFluoxetine sensitive group to see the specific brain alterations.",[185,186,187,188,28,189,190,191],"Constipation - Functional","Refractory Constipation","Fluoxetine","fMRI","Treatment Efficacy","Somatic Symptom","Mental Symptom",[188,193,194],"functional connectivity","refractory constipation","2025-07-22",{"date":197,"type":47},"2025-07-24",{"date":199,"type":47},"2023-11-01",{"date":201,"type":21},"2026-09-01",{"name":203,"class":54},"Xijing Hospital of Digestive Diseases",3,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":89,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":67,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":55},"100558816","investigating-the-effects-of-transcranial-direct-current-stimulation-to-different-brain-regions-on-ankle-tracking-motor-learning-motor-adaptation-and-brain-connectivity-in-healthy-middle-aged-and-older-adults-and-patients-with-subcortical-stroke-100558816","NCT06556043","Investigating the Effects of Transcranial Direct Current Stimulation to Different Brain Regions on Ankle Tracking Motor Learning, Motor Adaptation, and Brain Connectivity in Healthy Middle-aged and Older Adults and Patients With Subcortical Stroke","Investigating the Effects of Transcranial Direct Current Stimulation (tDCS) to Different Brain Regions on Ankle Tracking Motor Learning, Motor Adaptation, and Brain Connectivity in Healthy Middle-aged and Older Adults and Patients With Subcortical Stroke","tDCS","Inclusion Criteria: Part 1: healthy middle-aged and older adults\n\n1. age between 40 and 80 years old\n2. intact cognitive function (MMSE ≧ 27)\n3. normal ankle dorsiflexor and plantarflexor strength (manual muscle strength testing= 5) and passive range of motion (ankle dorsiflexion ≧10 degrees; ankle plantarflexion ≧ 45 degrees)\n4. corrected far vision ≥ 0.8 (Landolt C test) and uncorrected near vision ≥ 0.04 (Comprehensive Color Blindness Checklist)\n\nExclusion Criteria: Part 1: healthy middle-aged and older adults\n\n1. having any contraindications for MRI or tDCS;\n2. serious or uncontrolled systematic diseases;\n3. symptoms or history of neurological diseases, including transient ischemic attack, stroke, epilepsy, history of abnormal electroencephalogram (EEG), meningitis, encephalitis, brain tumors, brain surgery, and sensory disorders, etc.;\n4. severe musculoskeletal problems that would affect lower limb functions;\n5. visual spatial perception disorders and hearing loss;\n6. color blindness;\n7. depression and psychiatric disorders;\n8. use of any medication that could affect the central nervous system function;\n9. drug, substance, or alcohol addiction;\n10. those participating in research involving invasive or non-invasive brain stimulation;\n11. those deemed unsuitable for MRI or tDCS after evaluation by the attending physician;\n12. those affiliated with any research-conducting institution.\n\nInclusion Criteria: Part 2: patients with chronic subcortical stroke\n\n1. aged between 40 and 80 years old;\n2. intact cognitive function (MMSE ≥ 27);\n3. first-ever onset of subcortical stroke occurring at least 3 months prior to enrollment, with brain lesions involving unilateral subcortical regions only;\n4. hemiplegic or hemiparetic;\n5. no spatial neglect;\n6. able to actively perform at least 5 degrees of ankle dorsiflexion and 10 degrees of ankle plantarflexion with the affected ankle;\n7. no excessive spasticity;\n8. no severe contracture (passive range of motion ≥ 10 degrees for ankle dorsiflexion and ≥ 20 degrees for ankle plantarflexion) in the affected leg;\n9. mild-to moderate disability;\n10. can walk independently or under supervision without assistance;\n11. corrected far vision ≥ 0.8 (Landolt C test) and uncorrected near vision ≥ 0.04 (Comprehensive Color Blindness Checklist.)\n\nExclusion Criteria: Part 2: patients with chronic subcortical stroke The exclusion criteria will be the same as those listed for healthy participants described in Part 1 except for items (3) and (4). Item (3) will be changed to \"(3a) symptoms or history of other neurological diseases, including epilepsy, history of abnormal EEG, meningitis, encephalitis, brain tumors, brain surgery, and sensory disorders, etc.\" and item (4) will be changed to \"(4a) severe musculoskeletal problems of the non-hemiparetic limbs that would affect mobility functions\".","40 Years","80 Years",{"count":216,"type":21},120,[69],"Ankle control is essential to safe over-ground navigation for humans. Middle- aged and older adults and patients with stroke whose ankle control is poor often lose their balance or fall. Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technology that has great potential to be applied to neurorehabilitation; however, the optimization of its applications still needs further studies. The aims of this project are to compare the effects of anodal tDCS (AtDCS) applied to the primary motor cortex (M1) contralateral to the moving leg (cM1), posterior parietal cortex (PPC) contralateral to the moving leg (cPPC), and cerebellar cortex (CBM) ipsilateral to the moving leg (iCBM) on motor learning, motor adaptation, and brain connectivity in healthy middle-aged and older adults and hemiparetic patients with chronic subcortical stroke.",[220,221,222,223,154,28,224],"Transcranial Direct Current Stimulation","Ankle","Motor Learning","Adaptation","Stroke","2024-08-15",{"date":227,"type":47},"2024-08-19",{"date":229,"type":47},"2024-07-09",{"date":231,"type":21},"2026-07-31",{"name":233,"class":54},"National Taiwan University Hospital"]